Brief: Moleculin Biotech Inc - Completion Of Its Phase 1B/2 (Mb-106) Clinical Trial Evaluating Annamycin In Combination With Cytarabine
27/08/2025 13:48
Aug 27 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN BIOTECH INC - COMPLETION OF ITS PHASE 1B/2 (MB-106) CLINICAL TRIAL EVALUATING ANNAMYCIN IN COMBINATION WITH CYTARABINE MOLECULIN BIOTECH INC - MEDIAN OS OF 15 MONTHS FOR COMPLETE REMISSION SUBJECTS IN STUDY MOLECULIN BIOTECH INC - CLINICAL STUDY REPORT ANTICIPATED IN Q1 2026 Source text: ID:nGNX9my4wr Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM